MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that it has completed enrollment in a Phase II clinical trial to evaluate its Gabapentin GR compound for the treatment of patients with painful diabetic peripheral neuropathy (DPN). The company expects data from the approximately 150-patient trial to be available by year end 2006. This trial is in addition to, and separate from, the pivotal registration Phase III clinical trial that the company is conducting with Gabapentin GR to treat post-herpetic neuralgia.
